Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer by Paller, C.J. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
ORIGINAL RESEARCH
Combining the pan-aurora kinase inhibitor AMG 900 with
histone deacetylase inhibitors enhances antitumor activity
in prostate cancer
Channing J. Paller1,a, Michel D. Wissing1,2,3,a, Janet Mendonca1, Anup Sharma1, Eugene Kim1,
Hea-Soo Kim1, Madeleine S. Q. Kortenhorst1, Stephanie Gerber1, Marc Rosen1, Faraz Shaikh4,
Marianna L. Zahurak5, Michelle A. Rudek1, Hans Hammers1, Charles M. Rudin1, Michael A. Carducci1
& Sushant K. Kachhap1
1Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231
2Department of Clinical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
3Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100,3584 CX Utrecht, The Netherlands
4School of Medicine, Eastern Virginia Medical School, Norfolk, Virginia 23510
5Department of Oncology Biostatistics, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore,
Maryland 21231
Keywords
AMG 900, aurora kinase inhibitor, histone
deacetylase inhibitors, prostate cancer,
synergy, valproic acid, vorinostat
Correspondence
Sushant K. Kachhap, Sidney Kimmel
Comprehensive Cancer Center, Johns
Hopkins Medical Institutions, 1650 Orleans
Street CRB-I 1M53, Baltimore, MD 21287.
Tel: +14105026489; Fax: +14106148397;
E-mail: Kachhsu@jhmi.edu
Funding Information
This study was supported by the Flight
Attendant Medical Research Institute,
AEGON, NIH (T32: 5T32CA009071-29; core:
P30-CA006973-41S2), NCI SPORE Grant
P50CA58236, the Young Investigator Award
from the American Society of Clinical
Oncology Conquer Cancer Foundation, the
Paul Carbone Fellowship from the Eastern
Cooperative Oncology Group, and the
Community Foundation of the National
Capital Region.
Received: 22 March 2014; Revised: 8 May
2014; Accepted: 26 May 2014
Cancer Medicine 2014; 3(5): 1322–1335
doi: 10.1002/cam4.289
aThese authors contributed equally to the
work.
Abstract
Histone deacetylase inhibitors (HDACIs) are being tested in clinical trials for
the treatment of solid tumors. While most studies have focused on the reex-
pression of silenced tumor suppressor genes, a number of genes/pathways are
downregulated by HDACIs. This provides opportunities for combination ther-
apy: agents that further disable these pathways through inhibition of residual
gene function are speculated to enhance cell death in combination with HDAC-
Is. A previous study from our group indicated that mitotic checkpoint kinases
such as PLK1 and Aurora A are downregulated by HDACIs. We used in vitro
and in vivo xenograft models of prostate cancer (PCA) to test whether combi-
nation of HDACIs with the pan-aurora kinase inhibitor AMG 900 can synergis-
tically or additively kill PCA cells. AMG 900 and HDACIs synergistically
decreased cell proliferation activity and clonogenic survival in DU-145, LNCaP,
and PC3 PCA cell lines compared to single-agent treatment. Cellular senes-
cence, polyploidy, and apoptosis was significantly increased in all cell lines after
combination treatment. In vivo xenograft studies indicated decreased tumor
growth and decreased aurora B kinase activity in mice treated with low-dose
AMG 900 and vorinostat compared to either agent alone. Pharmacodynamics
was assessed by scoring for phosphorylated histone H3 through immunofluo-
rescence. Our results indicate that combination treatment with low doses of
AMG 900 and HDACIs could be a promising therapy for future clinical trials
against PCA.
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In recent years, the introduction of various novel therapies
for prostate cancer (PCA), such as taxanes, has significantly
extended survival of patients [1, 2]. Nevertheless, PCA
remains the second deadliest cancer in the Western world
[3]. Therefore, research is required to further improve
clinical outcomes by identifying therapies with improved
antitumor efficacy and/or reduced toxicities.
In the search for new molecular targets for PCA treat-
ment, aurora kinases are a promising candidate [4]. Three
paralogous genes (aurora A, B, and C) comprise the aur-
ora family of serine/threonine protein kinases in mamma-
lian cells. Aurora A and B are essential regulators of
mitosis, while aurora C primarily plays a role in meiosis.
Aurora A is an oncogene upregulated in several tumor
types [5]. Its phosphorylation is required for cell cycle
progression, centrosome maturation, and spindle assembly
[6, 7]. Aurora B, also overexpressed in tumor cells, is most
active during the G2/M-phase, and its phosphorylation is
essential for the final steps of cytokinesis [6, 8, 9]. Active
aurora B phosphorylates histone H3 on Serine 10, a
molecular event vital for chromosome condensation and
mitotic progression [6, 8]. Inhibition of aurora A and B
inactivates the spindle assembly checkpoint, resulting in
endoreduplication, polyploidy, and eventually, apoptosis
[6, 10–12]. The orally bioavailable pan-aurora kinase
inhibitor AMG 900 aborts cytokinesis by inhibition of
autophosphorylation of aurora kinases [11]. It is effective
in multidrug-resistant models, possibly through circum-
vention of the drug efflux effector P-glycoprotein [11].
AMG 900 may yield enhanced antitumor activity in the
presence of additional cancer therapeutics [11, 13]. Previ-
ous studies by our group have demonstrated that several
genes involved in mitotic checkpoints, including polo-like
kinase 1 (Plk1) and aurora kinases, are downregulated by
HDACIs [14, 15]. Recently, we have demonstrated that
combination of HDACIs with a Plk1 inhibitor synergisti-
cally induced apoptosis, decreased cell proliferation, and
decreased clonogenic survival of PCA cells [16]. Based on
our success with Plk1 inhibitors, we hypothesized that
addition of HDACIs could potentiate apoptosis in PCA
cells that are treated with Aurora kinase inhibitors. Fur-
ther, HDACIs exhibit promising antitumor effects in PCA
in vitro and in vivo [17, 18], and have successfully been
used in concert with other chemotherapeutics [19, 20].
Therefore, HDACIs could serve as a rational choice for
complementing the apoptotic effects of AMG 900. Hence,
we combined AMG 900 with the HDACIs VPA and
vorinostat in PCA cells in our current study [15]. We
found that combination of HDACIs with AMG 900 has a
synergistic antitumor effect, the HDACIs activating an
apoptotic mechanism in aurora kinase-inhibited PCA cells.
Material and Methods
In vitro
Cell culture and treatment
PCA cell lines (DU-145, LNCaP, PC3) were obtained
from ATCC. Cells were grown in RPMI-1640 (Invitrogen,
Carlsbad, CA) with 10% fetal bovine serum (FBS) (Gem-
ini, West Sacramento, CA) and maintained in a 37°C
humidified incubator supplemented with 5% CO2. VPA
(Sigma-Aldrich, St Louis, MO) was prepared in Roswell
Park Memorial Institute (RPMI) at a 1 mol/L stock on
the day of treatment of the cells. Vorinostat
(AtonPharma, Lawrenceville, NJ) and AMG 900 (Amgen,
Thousand Oaks, CA) were maintained in 10 mmol/L
dimethyl sulfoxide (DMSO) stock solutions at 20°C and
diluted in RPMI upon use. Compounds were adminis-
tered concomitantly in combination studies.
Cell viability and synergy
3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays
were performed with CellTiter 96TM Aqueous Nonradio-
active Cell Proliferation Assay reagent (Promega, Madi-
son, WI) according to the manufacturer’s instructions.
In brief, PCA cells were plated in 96-well plates, allowed
to adhere overnight and treated with the selected com-
pounds for 72 h. Subsequently, MTS reagent was added.
Absorption at 490 nm was measured after approxi-
mately 2 h using a colorimetric plate reader (Molecular
Devices, Sunnyvale, CA).
To compare the antitumor effect of single-agent treat-
ments with combination treatment, synergy was deter-
mined using CalcuSyn software (Biosoft, Cambridge,
U.K.). CalcuSyn calculates a combination index (CI) at
different levels of growth, using the formula for mutually
nonexclusive mechanisms: (D1/Dx1) + (D2/Dx2) + (D1 9
D2/Dx1 9 Dx2), where D1 and D2 are the doses of drug
1 and drug 2 in combination required to produce 9 per-
centage effect, and Dx1 and Dx2 are the doses of drug 1
and drug 2 alone required to produce the same effect.
Synergy levels (no synergy [CI > 0.9], moderate synergy
[0.7 < CI < 0.9, +], synergy [0.3 < CI < 0.7, ++], strong
synergy [0.1 < CI < 0.3, +++], very strong synergy
[CI < 0.1, ++++]) were determined from CI ranges, using
the Chou–Talalay method following the manufacturer’s
instructions [21, 22].
Cell survival
Clonogenic assays were performed to assess long-term cell
survival. PCA cells were plated in complete RPMI media.
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Upon reaching 50–60% confluency, drugs were added at
the appropriate concentration and dishes were incubated
for 48 h. Then cells (1.25 9 103 for DU-145 and PC3
cells, 2 9 103 for LNCaP cells) were replated and grown
in triplicate in 60 mm dishes containing fresh, complete
RPMI media. After 10–14 days (depending on the dou-
bling time of cell line), crystal violet stain (Sigma) was
used to stain colonies and colonies were counted. All
dishes from one cell line were stained at the same time
point. The average number of colonies in DMSO-treated
controls was considered 100% clonogenic survival in each
separate cell line and in each separate experiment. Stu-
dent’s t-tests were performed to assess whether clonogenic
survival of a cell line differed significantly between doses
of a single agent; synergy was determined with CalcuSyn
when comparing single-agent treatment with combination
treatment [21, 22].
Cellular senescence
PCA cells were plated in 6-well plates (25–50 9 103
cells per well) and allowed to adhere overnight. Com-
pounds were added to the complete RPMI media for
48 h, after which senescent cells were stained using the
senescence b-galactosidase-staining kit (Cell Signaling
Technology, Danvers, MA) according to the manufac-
turer’s instructions. In brief, cells were washed in phos-
phate buffered saline (PBS) and fixed in Fixative
Solution (2% formaldehyde and 0.2% glutaraldehyde in
19 PBS). After fixing, cells were washed in PBS and
incubated with Staining Solution (containing 40 mmol/L
citric acid/sodium phosphate [pH 6.0], 150 mmol/L
NaCl, 2 mmol/L MgCl2, 5 nmol/L potassium ferrocya-
nide, and 1 mg/mL X-gal in 5% dimethylformamide) in
a 37°C incubator for 24 h. Cells were washed in PBS
and visualized under an Olympus IX70 inverted micro-
scope (Tokyo, Japan) using an Uplan FL 109 phase
contrast lens. Multiple images (>5) were taken from
each well. Senescent (blue) and total cells were counted
in five fields of approximately 30 cells/field for each
treatment. Student’s t-tests were performed to determine
whether cellular senescence significantly differed between
combination treatment and single-agent treatment.
Fluorescence microscopy
Cells were drugged at 50–70% confluency for 48 h and
fixed with neutral-buffered formalin for 10 min, followed
by permeabilization with 0.125% Triton X-100 for 5 min.
Cells were blocked with 10% bovine serum albumin
(BSA) overnight. Cells were probed with a primary anti-
body against phosphorylated aurora kinase A/B/C (Anti-
body #2914; Cell Signaling Technology) at a 1:100
dilution followed by an Alexa Fluor-555 (Invitrogen) con-
jugated secondary antibody at a 1:400 dilution in blocking
buffer. Cells were washed in PBS and further incubated
with Alexa Fluor-488 conjugated phosphorylated histone
H3 antibody (antibody #9713 1:100 dilution; Cell Signal-
ing Technology). Cells were counterstained with Hoechst
33258 and mounted on slides. Confocal images were
taken with the Zeiss LSM 510 meta-confocal microscope
(Carl Zeiss, Thornwood, NY) using a 639 objective.
Flow cytometry
Cells were plated in 100 mm dishes and drugged at 50–
70% confluency. Both floating and attached cells were
collected 48 h after treatment, washed in PBS and fixed
with 4% freshly made paraformaldehyde. Cells were then
permeabilized with 90% cold methanol. Permeabilized
cells were stained with Alexa Fluor-488 conjugated phos-
phorylated histone H3 antibody (1: 100 dilution; Cell Sig-
naling Technology). Nuclei were stained with propidium
iodide (Sigma) in PBS containing 1% BSA. Flow cytome-
try was performed on a FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA). Cell cycle analysis was per-
formed using BD FACSDiva software and FlowJo.
Immunoblotting
Western blotting was performed as described previously
[14]. Loading volumes equal to 20 lg of total protein
were used. Primary antibodies were diluted 1:1000 in
blocking solution with the exceptions of vinculin (Mil-
lipore, Billerica, MA) and phosphorylated aurora A/B/C
(Antibody #2914; Cell Signaling Technology), which
were diluted 1:4000 and 1:500, respectively. Conjugated
secondary antibodies were diluted 1:4000 in blocking
solution. Blocking solution (5% milk in TBST (10
[mmol/L Tris-HCl pH 7.4, 0.1% Tween 20, 150 mmol/
L: NaCl in H2O]) was used to dilute antibodies against
p21 (BD Biosciences), cyclin B1 (Cell Signaling Tech-
nology), vinculin, and cleaved PARP (Cell Signaling
Technology), as well as all secondary antibodies. 5%
BSA was used for phosphorylated aurora A/B/C and
phosphorylated and total histone H3 (Cell Signaling
Technology). Blots were developed with enhanced
chemiluminescence (ECL) (GE) or Femto (Pierce Bio-
technology, Rockford, IL) and scanned into a computer
at a resolution of 300 dots per inch (dpi). Densitomet-
ric analyses were performed using ImageJ (Research
Services Branch, National Institute of Mental Health);
density of bands of the protein of interest was normal-
ized to the density of bands of the housekeeper (actin,
vinculin or total aurora A), and protein expression of
treated cells was compared to the control.
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In vivo
Animals
The animal protocol was approved by the Institutional
Animal Care and Use Committee (IACUC) of Johns Hop-
kins University. All IACUC guidelines and United States
Department of Agriculture regulations were followed. The
mice used in this study were 8-week old JHU Oncology
nonobese diabetic (NOD)/severe combined immunodefi-
ciency (SCIDs) (JHU bred colony) and were housed under
aseptic conditions on a 12-h light–dark cycle with food
and water provided ad lib. Each cage contained ≤5 mice,
which were differentiated by treatment groups.
Two million DU-145 PCA cells, suspended in complete
RPMI media, were embedded in a 1:2 solution of Matri-
gel (BD Biosciences) and injected subcutaneously into the
right flank of the mice. The tumor inoculation success
rate was approximately 90%. Following a 3-week growth
incubation period, tumor volume was estimated with dig-
ital calipers, using the standard formula: p/6 9 length 9
width 9 height. Before treatment initiation, mice were
stratified by tumor size and assigned into homogenous
groups (8–9 per group). Once average tumor volume was
above 200 mm3, treatment was initiated in all mice.
Treatments were administered four consecutive days per
week for a total duration of 4 weeks. Vorinostat (50 mg/
kg) was administered once daily via intraperitoneal injec-
tions on mornings of days 1–4 of the dosing cycle. AMG
900 was administered through gavage on days 1 and 2 of
each dosing cycle. Mice were treated with vehicle (2% hy-
droxylpropyl methyl cellulose [HPMC] and 1% Tween 80
in deionized water [pH 2.2] with methane sulfonic acid
[MSA]), or AMG 900 at a concentration of 3.75 mg/kg
or 7.5 mg/kg (provided weekly by Amgen in glycerin).
Tumor size and mice bodyweights were measured on the
day preceding each dosing cycle (day 0/7) and the final
day of dosing (day 4) each week. Tumors were harvested
when the volume reached 1000 mm3, which occurred 26–
35 days after start of the treatment. For histological
assessment of the tumors, mice were perfused with 2%
paraformaldehyde through a cardiac catheter, and then
tumors were excised, infiltrated in sucrose, embedded in
optimum cutting temperature (O.C.T.) compound (Sak-
ura Finetek, Tokyo, Japan), and stored at 80°C. Tissue
sections were prepared for hematoxylin–eosin staining by
fixing the tissue in formalin and embedding in paraffin
after tumor excision.
Tumor growth analysis
In vivo data from the DU-145 xenograft model were ana-
lyzed with a random intercept hierarchical linear model.
The primary statistical outcome was tumor volume. To
adjust for the initial volume, tumor volumes on days 3
through 26 for each mouse were divided by the volume
on day 0 and then the log of these values was taken for
analysis. The intercept in this longitudinal model was
specified such that it represented the log ratio of the final
tumor volume to the initial volume (time was coded
using negative numbers and 0 for the final day). The
model had the formula:
yit ¼ b0 þ f0i þ b1timeit þ b2groupi þ b3ðgroupi
 timesitÞ þ eit
where yit denotes the log ratio tumor volume for mouse i
at time t, b0 is the intercept representing the log ratio of
the tumor volume on day 26 to the initial volume for the
control group, b1 is the linear effect of time for the con-
trol group, b2 is the group effect on day 26, and b3 is the
group effect in terms of the linear effect of time. The
mouse-specific effect f0i represented the deviation of each
mouse from the group intercept. This is corrected for the
correlation between measurements taken on the same
mouse. Since the mice in this experiment were considered
a representative sample from a larger population, the
effect was considered random and it was assumed that
the population distribution from which they were sam-
pled had a normal distribution.
Tissue immunostaining
Sections (20 lm) were cut from frozen tissues and
mounted on microscope slides (Fisher Scientific, Wal-
tham, MA). Sections were blocked in blocking buffer (5%
goat serum, 0.5% BSA, 0.1% Triton X-100 and 0.01%
sodium azide in PBS) and probed overnight with the pri-
mary antibody phosphorylated histone H3 in a 1:100 dilu-
tion (antibody #9713; Cell Signaling Technology). Sections
were washed in PBS containing 0.1% Triton X-100 and
probed overnight with Alexa Fluor-546 conjugated anti-
rabbit antibody in a 1:500 dilution (Invitrogen). Subse-
quently, sections were washed in PBS and fixed with 10%
formalin, and nuclei were stained with DAPI (40,6-diami-
dino-2-phenylindole) present in the mountant (Invitro-
gen). Coverslips were mounted on the slides and sections
were imaged with a Nikon Eclipse Ti microscope at 209
(Nikon, Tokyo, Japan). The percentage of fluorescent cells
was assessed in at least three fields of view per treatment
group by dividing the density of red (phosphorylated his-
tone H3 positive cells) by the density of blue (DAPI stain-
ing all nuclei) staining with ImageJ. Student’s t-tests were
performed to assess for statistically significant differences
in the percentage of cells that stained positively for phos-
phorylated histone H3 and phosphorylated aurora A/B/C.
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Results
AMG 900 and HDACIs inhibit aurora kinase
expression and clonogenic survival of PCA
cells
After treatment of DU-145, PC3 and LNCaP PCA cells
with AMG 900 for 12 h, the relative decrease in protein
expression of phosphorylated aurora A/B/C was compared
to protein levels of total aurora A. In all three cell lines,
protein expression of phosphorylated aurora decreased in
a dose-dependent manner at concentrations above
1 nmol/L (Fig. 1A). Next, long-term clonogenic assays
were performed to determine cell survival of PCA cells
after AMG 900 treatment at 1 and 5 nmol/L. At 5 nmol/
L, AMG 900 effectively inhibited clonogenic survival in all
PCA cell lines (>70%) (Fig. 1B). These results mirrored
those of Payton et al., who reported that the IC50 of
AMG 900 in proliferation assays was around 5 nmol/L
for DU-145 and PC3 cells [11]. Based on aforementioned
results, we selected AMG 900 at 1 nmol/L (low dose, less
effective) and 5 nmol/L (high dose, effective) for drug
combination studies. VPA and vorinostat were adminis-
tered at concentrations of 1 mmol/L and 1.5 mmol/L,
and 0.5 lmol/L and 1 lmol/L, respectively, as at these
concentrations the compounds downregulated phosphory-
lated aurora A/B/C protein expression levels in DU-145
and PC3 cells (Fig. S1), while previous studies suggested
acceptable toxicities at these concentrations [16, 18, 23].
Combinations of low-dose AMG 900 with
HDACIs decrease proliferation activity and
clonogenic survival of PCA cells
We employed MTS and clonogenic assays to assess the
effect of combinations of AMG 900 with VPA and vori-
nostat on the proliferation activity and long-term survival
of PCA cells compared to single agent. In both assays,
treatment of PCA cells with 1 nmol/L AMG 900 did not
result in antitumor activity, similar to previous results
(compare Fig. 1 to Fig. 2). In MTS assays, low-dose VPA
combined with low-dose AMG 900 showed enhanced
inhibition of cell proliferation compared to high-dose
AMG 900 used as a single agent in both DU-145 and
LNCaP cells (Fig. 2A). Moderate synergistic effects were
observed in DU-145 cells treated with combinations of
AMG 900 (1 nmol/L) and VPA (1 mmol/L and
1.5 mmol/L) (CI = 0.796 and CI = 0.777, respectively),
and in LNCaP cells treated with combinations of AMG
900 (1 nmol/L) and VPA (1 mmol/L) (CI = 0.848) (Table
S1). In PC3 cells the proliferation, as evaluated by MTS
assays, was decreased by 10% at the most after treatment
with AMG 900 and/or VPA. Combinations of vorinostat
and AMG 900 enhanced the inhibition of cell prolifera-
tion in all three cell lines compared to treatment with sin-
gle agents, except when combining a low dose of
A
B
Figure 1. AMG 900 effectively targets PCA cells at concentrations
above 1 nmol/L. (A) Western blot quantifying the protein levels of
phosphorylated aurora A (48 kDa), B (40 kDa) and C (35 kDa) after
treatment of PCA cells with AMG 900 (concentrations indicated
above each lane) for 48 h. Bands were normalized to total levels of
aurora A. (B) Bar graph representing relative clonogenic survival after
AMG 900 treatment of PCA cell lines. Colonies were counted in
triplicate. PCA, prostate cancer.
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vorinostat (0.5 lmol/L) with a low-dose of AMG 900
(1 nmol/L) (Fig. 2B). Synergistic effects, as defined by
CalcuSyn, were observed in PC3 cells treated with combi-
nations of 1 lmol/L vorinostat and AMG 900 (1 nmol/L
and 5 nmol/L) (CI = 0.375 and CI = 0.558, respectively)
(Table S1) [21, 22].
Cell death through aurora kinase inhibition may
involve aborted cytokinesis progressing to apoptosis,
which may not be registered as a change in a short-term
proliferation assay. Therefore, we assessed the long-term
effect of combination treatment on clonogenic survival in
PCA cell lines. Treatment of PCA cells with 1 nmol/L
AMG 900 did not result in decreased clonogenic survival;
however, combinations of low-dose AMG 900 with either
VPA or vorinostat resulted in a remarkably decreased clo-
nogenic survival compared to single-agent treatment
(Fig. 2C and D). Subsequent analyses performed with
CalcuSyn demonstrated that administration of AMG 900
(1 nmol/L) combined with VPA (1 mmol/L and
1.5 mmol/L) resulted in a strongly synergistic decrease in
survival compared to the single compounds in DU-145
and PC3 cells (0.171 < CI < 0.260) (Fig. 2C, Table S1)
[21, 22]. In LNCaP cells a moderately synergistic decrease
in clonogenic survival was seen in combination treat-
ments of low-dose AMG 900 and low-dose VPA
(CI = 0.765). Treatment of cells with combinations of
AMG 900 (1 nmol/L) and vorinostat (0.5 and 1 lmol/L)
resulted in a decrease in clonogenic survival that was syn-
ergistic or moderately synergistic in all three PCA cell
lines (0.340 < CI < 0.809) (Fig. 2D, Table S1). The higher
dose of AMG 900 as a single agent severely inhibited clo-
nogenic survival in all three cell lines. As a result, virtually
no synergy could be measured in combination treatments
involving high-dose AMG 900.
A B
C D
Figure 2. Combinations of AMG 900 with HDACIs VPA and vorinostat decrease the proliferation activity and long-term clonogenic survival of
PCA cells compared to single-agent use. (A and B) Proliferation activity of PCA cells after treatment with AMG 900 and VPA (A) or vorinostat (B),
as measured by MTS assays. (C and D) Quantification of colonies to assess clonogenic survival of PCA cells after treatment with AMG 900 and
VPA (C) or vorinostat (D). Ai, AMG 900; +, moderate synergy; ++, synergy; +++, strong synergy; HDACI, histone deacetylase inhibitors; PCA,
prostate cancer; SAHA, suberanilohydroxamic acid (vorinostat); VPA, valproic acid.
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Combinations of AMG 900 with VPA or
vorinostat increase cellular senescence of
PCA cells
During MTS and clonogenic assays, we observed PCA cell
phenotypes resembling a senescent morphology after
treatment with AMG 900 with or without HDACIs. Trea-
ted cells displayed a flattened morphology compared to
untreated controls, and some treated DU-145 and PC3
cells showed cytoplasmic vacuoles and granularity. We
performed a Western blot analysis for p21 as a surrogate
marker of cellular senescence in PCA cells treated with
(combinations of) AMG 900 and HDACIs [24]. Protein
levels of p21 were not assessed in combinations with
high-dose AMG 900, as during the course of the treat-
ment, cells treated with this combination constituted
mainly apoptotic cells confounding analysis. In line with
previous studies [18, 25], protein expression of p21 was
significantly increased after HDACI treatment compared
to untreated controls; to a lesser extent AMG 900 treat-
ment also resulted in an increase in p21 protein levels
(Fig. 3A). Combination treatment further increased p21
levels, suggesting increased cellular senescence. To ascer-
tain whether cellular senescence is indeed increased after
combination treatment compared to single-agent use in
PCA cells, we stained DU-145, PC3 and LNCaP cells for
senescence-associated b-galactosidase (SA b-gal) enzyme
activity (Figs. 3B and S2). Consistent with our previously
observed morphological transformations, DU-145 and
PC3 cells treated with combinations of AMG 900 and
HDACIs had increased SA b-galactosidase staining.
LNCaP cells had a baseline level of blue SA b-galactosi-
dase staining in untreated controls; combination treat-
ment of LNCaP cells with AMG 900 and HDACIs
resulted in increased SA b-galactosidase staining. Quanti-
fication of b-galactosidase-positive cells confirmed that
the percentage of senescent cells was significantly
increased in PCA cells treated with combinations of AMG
900 and HDACIs (35–60% SA b-galactosidase positive
cells) compared to cells treated with single agents alone
(≤25% SA b-galactosidase positive cells) (P ≤ 0.05),
except for combination treatment of LNCaP cells with
AMG 900 (1 nmol/L) and vorinostat (0.5 lmol/L) com-
pared to cells treated with vorinostat alone (P = 0.116)
(Fig. 3C).
Combination treatment with AMG 900 and
HDACIs increases PCA cells with multipolar
spindles and polyploidy as compared to
single-agent treatment
Since aurora kinases localize to distinct subcellular struc-
tures in mitotic cells, we probed DU-145 and PC3 cells
with an antibody against phosphorylated aurora kinase
A/B/C to investigate whether treatment results in differ-
ences in localization of these enzymes (Fig. 4). We co-
stained the cells for phosphorylated histone H3 as histone
H3 is phosphorylated at Ser 10 by aurora B during mito-
sis and can therefore be used as a marker for aurora B
activity [26]. After treatment with AMG 900, alone or in
combination with HDACIs, localization of aurora was
limited to the spindle poles. It was further observed that
PC3 cells treated with low-dose AMG 900 and HDACIs
exhibited multipolar spindles, similar to 5 nmol/L of
AMG 900, suggesting endoreduplication and polyploidy.
Both cell lines showed a near complete loss in aurora
staining after a combination treatment with 5 nmol/L of
AMG 900 and HDACIs. Of note, addition of AMG 900
also caused a decrease in histone H3 phosphorylation in a
dose-dependent manner in both PCA cell lines, with DU-
145 demonstrating a greater decrease compared to PC3
cells. These results demonstrate that AMG 900 inhibits
aurora kinases in PCA cells, potentially causing an
increase in multipolar polyploid cells.
To further quantify the effects of combining HDACIs
and AMG 900 in PCA cells, we performed cell-cycle
analysis after treatment (Fig. 5A and B). Cells were
stained with phosphorylated H3 as a marker of aurora
kinase activity. It is also a marker for cells in mitosis.
DU-145 cells exhibited the greatest dose-dependent
decrease in phosphorylated histone H3 positive cells upon
AMG 900 treatment (Fig. 5A). In both cell lines, combi-
nation treatment resulted in an additional decrease in
phosphorylated histone H3 positive cells, most evidently
after combination therapy with the HDACI vorinostat. As
expected, flow cytometry showed AMG 900 alone induced
polyploidy in a dose-dependent manner with DU-145
cells exhibiting increased polyploidy as compared to
LNCaP and PC3 (Fig. 5B). Combinations of vorinostat
and low-dose AMG 900, again to a greater extent than
VPA and low-dose AMG 900, led to a much greater
increase in polyploidy as compared to single agents across
PCA cell lines investigated.
All above data pointed to enhanced antitumor effects
after treatment with a combination of low concentration
of AMG 900 with HDACIs. To investigate whether com-
binations led to increased apoptosis, we probed PCA cells
for cleaved PARP, a marker for apoptosis. As expected,
combination treatments with low-dose AMG 900 resulted
in an increase in PARP cleavage (Fig. 5C). DU-145 cells
exhibited a greater increase in PARP cleavage as com-
pared to PC3 cells. These data demonstrate that AMG
900 can effectively inhibit aurora kinase activity in PCA
cells, although the degree of inhibition may differ between
cell types. Addition of an HDACI further potentiates
apoptosis.
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Low-dose AMG 900 in combination with
vorinostat inhibits histone H3
phosphorylation and suppresses growth of
DU-145 xenografts
The effect of combination treatment with AMG 900 and
HDACIs on in vivo tumor growth inhibition was evalu-
ated in mice bearing DU-145 xenografts. Vorinostat was
selected as HDACI in these experiments, as it is already
approved for the treatment of cancers in humans and the
treatment administration does not require continuous
administration as does VPA in mice [18]. Mice were
treated with vehicle alone, with AMG 900 at 3.75 (low
dose) or 7.5 mg/kg (high dose), and/or with vorinostat at
50 mg/kg, corresponding to doses that had been used
previously with limited toxicity [11, 27]. The mean tumor
growth during treatment is depicted in Figure 6A. We
used the random intercept model to assess the overall
effects for time, group, and the time by group interaction,
which were all significant (interaction P < 0.0001, for
details please refer to Data S1). Specifically, the tumor
growth rate in mice after single-agent treatment with
high-dose AMG 900 and combination treatment with
either low- or high-dose AMG 900 and vorinostat was
significantly reduced compared to the tumor growth rate
in control mice (P-values 0.020, 0.014, and 0.036, respec-
tively) (Tables S3–S5). In the group treated with a combi-
nation of low-dose AMG 900 and vorinostat the average
tumor growth rate was also lower than the tumor growth
rate in groups treated with low-dose AMG 900 alone or
vorinostat alone (P = 0.003 and P = 0.008, respectively).
Tumor growth rates in mice treated with low-dose AMG
900 and vorinostat combination treatment were similar to
tumor growth rates in mice treated with high-dose AMG
900 (P = 0.833) and in mice treated with high-dose AMG




Figure 3. AMG 900 combined with HDACIs VPA or vorinostat
increases cellular senescence in PCA cell lines compared to single-agent
use. (A) Western blot for p21, a marker of cellular senescence or a G1/
G2 phase cell cycle arrest, after treating DU-145, LNCaP and PC3 cells
as indicated above each lane. Bands were normalized to the
housekeeper vinculin. Ai, AMG 900. (B) Representative images of PC3
cells after performing an SA b-galactosidase assay. Blue cells are SA
b-galactosidase positive cells, indicating cellular senescence. Ai, AMG
900. (C) Quantification of SA b-galactosidase-positive staining after
treatment of PCA cells with AMG 900 and/or HDACIs VPA/vorinostat.
Ai, AMG 900; * combination treatments with a significantly increased
percentage of senescent cells (P ≤ 0.05). HDACI, histone deacetylase
inhibitors; PCA, prostate cancer; SAHA, suberanilohydroxamic acid
(vorinostat); VPA, valproic acid.
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These data are in concordance with our in vitro find-
ings that the combination of low-dose AMG 900 and
HDACIs enhances inhibition of tumor cell growth. As the
groups receiving combination treatment did not exhibit a
significant difference in overall bodyweight compared to
vehicle-treated controls and did not show signs of severe
toxicity (no diarrhea or lethargy), our data suggest that
combination treatment resulted in few toxicities in mice
with stable weight (Tables S6 and S7, Figs. S5–S7).
Tumors from sacrificed mice were stained for phos-
phorylated histone H3 to assess aurora B inhibition
(Fig. 6B). Vehicle- and vorinostat-treated tumors dis-
played about 4% phosphorylated histone H3 positive
staining (P = 0.713), while treatment with low-dose
AMG 900 decreased the percentage of phosphorylated
histone H3 positive cells to about 2% (P = 0.004)
(Fig. 6C). Both combination treatment with low-dose
AMG 900 and vorinostat, and treatment with high-dose
AMG 900 alone or in combination with vorinostat
resulted in 0.5% of the DU-145 cells being stained posi-
tively for phosphorylated histone H3, indicating signifi-
cantly inhibited aurora B kinase activity in these tumors
compared to vehicle-treated tumors (P < 0.001 and
P = 0.001, respectively). Inhibition of aurora B kinase
activity did not differ between the combination treatment
with low-dose AMG 900 and vorinostat and high-dose
AMG 900 alone (P = 0.806).
Discussion
Tumor cell resistance and dose-limiting toxicities fre-
quently result in administration of molecularly targeted
agents below the efficacy threshold in patients. The
efficacy of treatment could be increased by rationally
combining antitumor therapies. Previously, we applied
analysis of functional annotation (AFA) to analyze data
from a microarray experiment with VPA- or vorinostat-
treated PCA cells that demonstrated HDACI-induced
changes in gene expression in these cells [23]. These data
highlighted multiple pathways that were up- or downreg-
ulated by vorinostat and VPA in PCA cells [15]. One can
envisage pathways downregulated by HDACIs as opportu-
nities for combining treatment modalities that are ineffec-
tive in the pathways’ presence. Several genes involved in
the mitotic spindle checkpoint were downregulated by
HDACI treatment, such as aurora kinase inhibitors,
pointing to combinations of HDACIs with mitotic spindle
checkpoint inhibitors as a promising anticancer strategy
[14]. Combination therapy of aurora kinase inhibitors
with HDACIs had promising results in preclinical experi-
ments with blood cancers [28, 29]; such combinations
have not been assessed in solid tumors. For this purpose,
we successfully combined AMG 900, a pan-aurora kinase
inhibitor, with HDACIs VPA and vorinostat in PCA cells
in this study. AMG 900 is currently being tested in phase
Figure 4. Confocal analysis of DU-145 and PC3 PCA cells treated with AMG 900 (1 or 5 nmol/L) and HDACIs VPA (1 mmol/L) and vorinostat
(1 lmol/L) stained for phosphorylated histone H3 (green) and phosphorylated aurora kinase A/B/C (red). AMG 900 causes a decrease in
phosphorylated histone H3 and an increase in multipolar spindles in a dose-dependent manner. PC3 cells also demonstrate multipolar spindles
when treated with a combination of lower concentrations of AMG 900 and HDACIs. Ai, AMG 900; HDACI, histone deacetylase inhibitors; SAHA,
suberanilohydroxamic acid (vorinostat); VPA, valproic acid.
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I clinical trials in patients with advanced solid tumors
and in patients with acute leukemias [30]; vorinostat is
FDA approved with a primary indication for cutaneous
T-cell lymphoma.
Our data indicate that combining aurora kinase inhibi-
tors with HDACIs yields additive and even synergistic
effects in inhibiting growth of both androgen-dependent
(LNCaP) and androgen-independent (DU-145, PC3) PCA
cell lines. We propose that multiple factors contribute to
the observed synergy: (1) HDACIs target cells in different
stages of the cell cycle (interphase) than AMG 900 (mito-
sis) [11, 31]. It is conceivable that cells which escape
A B
C
Figure 5. Flow cytometry analysis of PCA cell lines treated with AMG 900 (1 or 5 nmol/L) and HDACIs VPA (1 mmol/L) and vorinostat (1 lmol/L).
(A) Scatter plots show a decrease in phosphorylated histone H3 in PCA cells treated with AMG 900 in a dose-dependent manner. Cells treated with
a combination of vorinostat and low-dose AMG 900 show a marked decrease in phosphorylated histone H3 as compared to single-agent
treatment. (B) Cell cycle analysis indicates that AMG 900 causes an increase in polyploidy in all PCA cell lines in a dose-dependent manner. Low-
dose combination of AMG 900 with HDACIs cause an increase in polyploidy as compared to single-agent treatment. Ai, AMG 900. (C) Western blot
analysis for cleaved PARP in PCA cells treated with AMG 900 and/or HDACIs (the treatment is indicated above each lane). Bands were normalized
to the housekeeper actin. Ai, AMG 900; HDACI, histone deacetylase inhibitors; PCA, prostate cancer; SAHA, suberanilohydroxamic acid (vorinostat).
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targeting by AMG 900 and progress through mitosis
would be inhibited by HDACIs; (2) HDACIs may com-
plement the action of the aurora kinase inhibitor by
directly upregulating expression of genes that trigger the
apoptotic/senescence pathway, such as p21, p27, and
Bcl-2 [28, 32]; (3) HDACIs also target aurora kinases but
from a transcriptional angle instead of by direct catalytic
inhibition, therefore the aurora kinase pathway is targeted
more effectively with combination therapy [33–35]; and
(4) our data indicate that combinations of HDACIs and
AMG 900 could trigger senescense. Senescence is known
to be induced by activation of p21/Cip1 via p53 [24].
However, AMG 900 induces p21/Cip1 proteins in LNCaP,
which has a wild-type p53, and PC3 and DU-145 cells,
which are p53 null and mutant, respectively. This indi-
cates that p21 is induced independently of p53. In line
with this observation, HDACIs are known to induce p21
and senescence independently of the p53-p21 pathway
[32, 36, 37]. Intriguingly, the antitumor effect of AMG
900, enhanced with HDACIs, was more pronounced in
clonogenic assays than in MTS assays. In line with previ-
ous studies with aurora kinase inhibitors, we therefore
hypothesized endoreduplication to be the mechanism of
action [10, 11, 38]. Though this process inexorably leads
to cell death, it may, prior to that point, leave mitochon-
drial activity unaffected. Our cell cycle and microscopic
imaging analysis results demonstrated an increase in poly-
ploidy and senescence after AMG 900 treatment, support-
ing this theory.
Consistent with our in vitro observations, tumor growth
rates were lower in mice with a DU-145 xenograft model
that were treated with a combination of low-dose AMG
A B
C
Figure 6. Low-dose AMG 900 in combination with vorinostat enhances growth suppression of DU-145 xenografts and inhibits histone H3
phosphorylation in vivo, similar to treatment with high-dose AMG 900. (A) Tumor growth curves of NOD/SCID mice bearing established DU-145
tumors treated with vehicle alone, AMG 900 and/or vorinostat for a maximum of 4 weeks. Tumor volumes are represented as mean  SEM
(n = 9). *treatment groups that had a significantly different tumor growth rate compared to the vehicle-treated group (P ≤ 0.05). (B)
Representative images of tumor sections stained with phosphorylated histone H3 (red) and DAPI (blue) indicate decreased phosphorylated histone
H3-positive cells after AMG 900 treatment and combination treatment. (C) Bar graph quantifying the percentage of phosphorylated histone H3-
positive cells per treatment group. Student’s t-tests confirm significantly decreased phosphorylated histone H3 staining after high-dose AMG 900
treatment and after combination treatment. *treatment groups that had significantly less phosphorylated histone H3-positive cells compared to
the vehicle-treated group (P ≤ 0.05). Ai, AMG 900; NOD, nonobese diabetic; pH3, phosphorylated histone H3; SAHA, suberanilohydroxamic acid
(vorinostat); SCID, severe combined immunodeficiency.
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900 and vorinostat, than in comparable mice treated with
each individual agent at low doses. Growth rates in mice
given combination treatment were equivalent, however, to
those found in mice treated with high-dose AMG 900
alone. Prior research noted that AMG 900 blocks phos-
phorylated histone H3 in a dose-dependent manner in
multiple human tumor xenograft models [11]. Pharmaco-
dynamic analysis in our study demonstrated that low-dose
AMG 900 in combination with low-dose vorinostat blocks
phosphorylated histone H3 with efficacy similar to that of
high-dose AMG 900.
In conclusion, combination treatment of low-dose
AMG 900 with HDACIs could prove to be a viable mode
of therapy in solid tumors such as PCA. Clinically, a regi-
men combining lower concentrations of HDACIs and
AMG 900 could thereby yield 1) increased efficacy
through synergistic or additive mechanisms, and/or 2)
decreased toxicity. As VPA, vorinostat and AMG 900 dif-
fer in dose-limiting toxicities, the combination is not
expected to severely increase the odds of a dose-limiting
toxicity [30, 39–41]. Therefore, this combination of tar-
geted therapies could be a candidate for clinical trials as
forward-seeking translational research aimed at improving
clinical outcomes in cancer patients.
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